Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer

T. Enomoto,A. Tamiya,K. Matsumoto,Y. Adachi,K. Azuma,Y. Inagaki, S. Kouno,Y. Taniguchi,N. Saijo,K. Okishio,S. Atagi

Annals of Oncology（2020）

引用 3|浏览43

暂无评分

摘要

No significant benefits were associated with continuation of nivolumab for advanced NSCLC patients. Continuation of nivolumab beyond PD could be a more useful option in patients without new lesions at first PD. Treatment-related toxicities require attention during nivolumab treatment not only before PD but also beyond PD.

查看译文

关键词

Disease progression,Immunotherapy,Nivolumab,Non-small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要